\n| Subject<\/td>\n | \nThe 2025 Annual Shareholders' Meeting passes to\r\nrelease the prohibition on directors from participation\r\nin competition businesses.<\/pre>\n<\/td>\n<\/tr>\n\n| Date of events<\/td>\n | 2025\/06\/26<\/td>\n | To which item it meets<\/td>\n | paragraph 21<\/td>\n<\/tr>\n | \n| Statement<\/td>\n | \n1.Date of the shareholders meeting resolution:2025\/06\/26\r\n2.Name and title of the director with permission to engage in competitive\r\nconduct:\r\nDirector:Fu Hui-Tung\r\nDirector:Chang Ming-Cheng\r\nDirector:Hsieh Yen-Sheng\r\nDirector:Excelsior Group Holdings Co., Ltd. Representative:Chen Tun-Ling\r\nDirector:Excelsior Group Holdings Co., Ltd. Representative:Chang Hsien-Cheng\r\nDirector:Fu Jo-Hsuan\r\nIndependent director:Chan,Chien-Lung\r\nIndependent director:Kuo,Ming-Yi\r\nIndependent director:Huang,Chung-Chen\r\n3.Items of competitive conduct in which the director is permitted to engage:\r\nConcurrently serve as a director with the same or similar business scope\r\nas the Company.\r\n4.Period of permission to engage in the competitive conduct:\r\nA director's term of office\r\n5.Circumstances of the resolution (please describe the results of voting in\r\naccordance with Article 209 of the Company Act):\r\nThe resolution was adopted by a majority of the shareholders presented at\r\nthe general meeting who represented two-thirds or more of the total number\r\nof shares represented by the attending shareholders.\r\n6.If the permitted competitive conduct belongs to the operator of a mainland\r\nChina area enterprise, the name and title of the directors\r\n(if it is not the operator of a Mainland-area enterprise, please enter\r\n\u201cN\/A\u201d below):\r\nDirector:Chang Ming-Cheng\r\nDirector:Fu Jo-Hsuan\r\n7.Company name of the mainland China area enterprise and the director's\r\nposition in the enterprise:\r\nDirector:Chang Ming-Cheng\uff0cDirector of SinoExcelsior Investment\r\nIncorporation.\r\nDirector:Fu Jo-Hsuan\uff0cDirector of SinoExcelsior Investment Incorporation.\r\n8.Address of the mainland China area enterprise:\r\nSinoExcelsior Investment Incorporation address:\r\nRoom 301-2, No.1089, Kang Ning Road, Shanghai,China\r\n9.Operations of the mainland China area enterprise:\r\nSinoExcelsior Investment Incorporation:Enterprise management consulting,\r\nSales of Class I medical devices, Import and export of goods, Import and\r\nexport of technology, Internet sales (excluding goods requiring licensing),\r\nSales agency services, Health consultation services (excluding medical\r\ndiagnosis and treatment services),Information consulting services (excluding\r\nlicensed information consulting services), Technical services, technical\r\ndevelopment, technical consulting, technical exchange, technology transfer,\r\nand technology promotion, Marketing planning, Wholesale of cosmetics.\r\n(Except for projects that require approval according to the law, the company\r\nshall independently carry out business activities in accordance with the\r\nbusiness license)\r\n10.Impact on the company's finance and business:None.\r\n11.If the directors have invested in the mainland China area enterprise,\r\nthe monetary amount of the investment and their shareholding ratio:None.\r\n12.Any other matters that need to be specified:None.<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":" SEQ_NO \u00a03 Date of announcement 2025\/06\/26 Time of announcement 14:56:31 Subject The 2025 Annual Shareholders’ Meeting passes to release the prohibition on directors from participation in competition businesses. Date of events 2025\/06\/26 To which item it meets paragraph 21 Statement 1.Date of the shareholders meeting resolution:2025\/06\/26 2.Name and title of the director with permission …<\/p>\n The 2025 Annual Shareholders’ Meeting passes to release the prohibition on directors from participation in competition businesses.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-9963","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=9963"}],"version-history":[{"count":1,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9963\/revisions"}],"predecessor-version":[{"id":9964,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9963\/revisions\/9964"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=9963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=9963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=9963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | |